Kornimate/medical-research-clean huggingface dataset:
gluteus maximus versus gluteus medius strength on back muscles performance in patients with sacroiliac dysfunction

Conditions: Sacroiliac Joint Dysfunction

Summary: this study will be conducted to compare between the effect of glutes maximus and glutes medius muscles strength on back muscle performance in patients with sacroiliac joint dysfunction.

the purposes of this study are: 1. to investigate the effect of gluteus maximus strengthening exercises and gluteus medius strengthening exercises on back pain in patient with sacroiliac joint dysfunction 2. to investigate the effect of gluteus maximus strengthening exercises and gluteus medius strengthening exercises on back muscle performance in patients with sacroiliac joint dysfunction 3. to investigate the effects of gluteus maximus strengthening exercises and gluteus medius strengthening exercises on function in patient with sacroiliac joint dysfunction

Eligibility criteria:
inclusion criteria: * age from 25-40 years. * patients with chronic lumbopelvic pain (more than 12 weeks) and clinical test positive for sijd. * the pain distribution and tenderness on palpation under the posterior superior iliac spine (psis) are reliable signs that the sij is the source of pain. * complaint of unilateral pain rather than bilateral pain is also considered more likely to be coming from an sij. * patients willing and able to participate in an exercise program safely and without cognitive impairments that would limit their participation. exclusion criteria: * neurological disorder, psychosomatic disorder * tumor. * infection condition. * recent surgeries. * pregnancy. * back pain referred from organic cause. * osteoporosis and bone disease (induced or idiopathic).
hope (harnessing online peer education): using online social networks for hiv prevention and testing

Conditions: HIV

Summary: this study seeks to determine whether social networking technologies can be used to increase hiv prevention and testing.the hope (harnessing online peer education) model seeks to apply a diffusion of innovations style intervention to social media to increase hiv testing.


Eligibility criteria:
inclusion criteria: * 18 years or older * has had sex with a man in the past 12 months * lives in lima or callao, peu * has a facebook account or willing to create one exclusion criteria: * does not satisfy inclusion criteria

Keywords: hiv social networking at-risk populations sexual risk behaviors
musculoskeletal problems during pregnancy

Conditions: Most Common Musculoskeletal Problems in Pregnancy

Summary: aim: this study was conducted to identify the most common musculoskeletal problems according to trimester, experienced by pregnant women. material and methods: a total of 120 pregnant women who admitted to physical medicine and rehabilitation clinic, evaluated retrospectively in this study. application complaints, the diagnosis and the trimester of the pregnant women and also age, weight, height, number of pregnancy, working status, presence of secondary disease were recorded.


Eligibility criteria:
inclusion criteria: pregnant patients who have age, weight, size, employment status, duration of pregnancy, nulli/multi-parity, presence of other disorders, application complaints, the diagnosis information were included to the study exclusion criteria: non-pregnant patients and pregnant patients with missing data were excluded from the study

Keywords: carpal tunnel syndrome low back pain pelvic girdle pain
a study to evaluate the safety of lebrikizumab compared to topical corticosteroids in adult patients with atopic dermatitis

Conditions: Atopic Dermatitis

Summary: the primary objective for this study is to evaluate the safety of lebrikizumab compared with topical corticosteroids (tcs) alone in patients with persistent moderate to severe atopic dermatitis (ad) that is inadequately controlled with tcs.


Eligibility criteria:
inclusion criteria: * age 18 to 75 years, inclusive, at the start of the run-in period * ad diagnosed by the hanifin/rajka criteria and that has been present for at least 1 year at screening * moderate to severe ad as graded by the rajka/langeland criteria at screening * history of inadequate response to a \>/= 1 month (within the 3 months prior to the screening visit) treatment regimen of at least daily tcs and regular emollient for treatment of ad * easi score \>/= 14 at screening * iga score \>/= 3 * ad involvement of \>/= 10% body surface area * pruritus visual analog scale score \>/= 3 exclusion criteria: * past and/or current use of any anti-il-13 or anti-il-4/il-13 therapy, including lebrikizumab * use of an investigational agent within 4 weeks prior to screening or within 5 half-lives of the investigational agent, whichever is longer * evidence of other skin conditions, including, but not limited to, t-cell lymphoma or allergic contact dermatitis * history of a severe allergic reaction or anaphylactic reaction to a biologic agent or known hypersensitivity to any component of the lebrikizumab injection * use of any complementary, alternative, or homeopathic medicines including, but not limited to, phytotherapies, traditional or non-traditional herbal medications, essential fatty acids, or acupuncture within 7 days prior to the run-in period or need for such medications during the study * evidence of other skin conditions; including, but not limited to, t-cell lymphoma or allergic contact dermatitis * evidence of, or ongoing treatment (including topical antibiotics) for active skin infection at screening * other recent infections meeting protocol criteria * active tuberculosis requiring treatment within the 12 months prior to visit 1 * evidence of acute or chronic hepatitis or known liver cirrhosis * known immunodeficiency, including hiv infection * use of a topical calcineurin inhibitor (tci) at the time of screening, unless the patient is willing to stop tci use during the study (including the run-in period) and, in the investigator's opinion, it is safe to do so * clinically significant abnormality on screening ecg or laboratory tests * known current malignancy or current evaluation for a potential malignancy, including basal or squamous cell carcinoma of the skin or carcinoma in situ * history of malignancy within 5 years prior to screening, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, stage i uterine cancer
a comparison of two dose levels of indinavir combined with two nucleoside analogue reverse transcriptase inhibitors (nrtis) in hiv-infected patients

Conditions: HIV Infections

Summary: the purpose of this study is to determine if two dose levels of indinavir combined with two nucleoside analogue reverse transcriptase inhibitors (nrtis) have the same effect on plasma viral load (level of hiv in the blood).

in this open-label study 350 seropositive hiv-1 men and women are first stratified according to baseline plasma viral rna (less than 400 copies/ml vs negative plasma viral rna result) then randomized into one of two arms: arm 1: indinavir (800 mg, q8h) plus two pre-existing nrtis. arm 2: indinavir (1,200 mg, q12h) plus two pre-existing nrtis. plasma viral rna will be measured every 4 weeks for the duration of the 24-week study.

Eligibility criteria:
inclusion criteria patients must have: * documented hiv-1 seropositive status. * cd4 count greater than 100 cells/mm3. * parental consent for patients under 18.

Keywords: hiv-1 dose-response relationship, drug hiv protease inhibitors indinavir rna, viral reverse transcriptase inhibitors
heart failure with improved ejection fraction and deep learning

Conditions: Heart Failure; Diagnosis

Summary: the aim of this study was to design a deep learning-based trained model to assist in hfimpef diagnosis.


Eligibility criteria:
inclusion criteria: 1. age \>18 years. 2. the diagnostic criteria of hf follows the 2018 chinese guidelines for the diagnosis and treatment of heart failure, having symptoms of dyspnea, fatigue or decreased activity tolerance, having signs of fluid retention (such as pulmonary congestion and peripheral edema), having echocardiogram abnormalities in cardiac structure and/or function, showing elevated natriuretic peptide levels (bnp\>35 ng/l or/and n-terminal pro-bnp \>125 ng/l). 3. have reviewing echocardiography after discharge. exclusion criteria: 1. patients with hypertrophic, restrictive, or invasive cardiomyopathy and congenital or rheumatic heart disease. 2. patients with heart transplantation during follow-up.

Keywords: heart failure left ventricular ejection fraction heart failure with improved ejection fraction deep learning
intraoperative use of perineal block for hemorrhoidectomy

Conditions: Hemorrhoidectomy; Pudendal Nerve

Summary: perineal block with the anesthesia of the pudendal nerve's terminal branches allows to perform a hemorrhoidectomy with the optimal intraoperative and postoperative analgesia the purpose of this study is to assess the effectiveness of the intraoperative use of perineal block with spinal anesthesia to reduce postoperative pain and the amount of used analgesics.

hemorrhoidectomy, as has being demonstrated to be an effective method of treatment for stage iii-iv hemorrhoidal disease. however it is associated with intense postoperative pain that requires the use of multimodal analgesia. inadequate pain control leads to the prolongation of admission, increasing the consumption of opioid analgesics. traditionally spinal or general anesthesia is used in proctological practice. however, the number of studies about using of perianal local anesthesia, both in combination with general anesthesia and as a separate practice has been increasing recently. perineal block with the anesthesia of the pudendal nerve's terminal branches allows to perform a hemorrhoidectomy with the optimal intraoperative and postoperative analgesia. the drugs used for this have some pharmacological differences in the duration of the drug and the form of administration. the aim of this prospective, randomized, double-blind study is to assess the effectiveness of the intraoperative use of perineal block with spinal anesthesia to reduce postoperative pain and the amount of used analgesics.

Eligibility criteria:
inclusion criteria: 1. written informed consent. 2. patients over 18 years. 3. symptomatic grade iii-iv hemorrhoids. 4. planned surgery: milligan-morgan hemorrhoidectomy. exclusion criteria: 1. patient's refuse to participate in the study. 2. pregnancy. 3. сontraindications or technical inability to perform subarachnoid anesthesia. 4. decompensated somatic diseases. 5. inflammation of the perianal region.

Keywords: perineal block hemorrhoidectomy hemorrhoids hemorrhoids treatment pudendal nerve
dbt skills plus emdr for bpd and trauma

Conditions: Borderline Personality Disorder; Trauma

Summary: borderline personality disorder (bpd) is a severe disorder that frequently co-occurs with post-traumatic stress disorder (ptsd). the comorbidity of bpd and ptsd is more disabling, predicting lower rates of bpd remission. dialectical behavioral skills training (dbt-st), is a group-delivered training that covers four types of skills: emotion regulation, mindfulness, interpersonal effectiveness and distress tolerance. as a stand-alone treatment, research suggest that dbt-st is an efficacious treatment for bpd. in parallel, emdr has emerged in last years as an efficacious approach to adult trauma. however, so far, the efficacy of emdr to treat trauma in populations with bpd diagnosis has not been tested. the present pilot randomized-controlled clinical trial aims to test whether a combination of dbt-st plus emdr could be efficacious to treat trauma in individuals with bpd. 40 participants will be recruited from the bpd unit at the hospital de la santa creu i sant pau (barcelona, spain) and will be randomized (1:1) to dbt-st + emdr or dbt-st alone. the primary outcome will be the reduction of ptsd symptoms. in addition, symptom-related variables will be collected before and after the interventions. this will be the first study to test the combination of dbt-st and emdr.


Eligibility criteria:
inclusion criteria: * men and women between 18 and 60 years old * having had adverse childhood experiences and/or current ptsd symptoms * signed informed consent exclusion criteria: * lifetime diagnosis of schizophrenia, drug-induced psychosis, organic brain syndrome, bipolar disorder, or mental retardation. * participation in any psychotherapy during the study or having received dbt or emdr in the past
mycophenolate mofetil versus azathioprine for maintenance therapy of lupus nephritis

Conditions: Lupus Nephritis

Summary: this study is designed to compare the safety and efficacy of mycocep capsules (mycophenolate mofetil) and a marketed azathioprine formulation, imuran azathioprine tablets, in the maintenance therapy of lupus nephritis.

this study is designed to compare the two different doses of mycocep capsules (1.0g/day \& 1.5g/day) and imuran azathioprine tablets (2mg/kg/day), all in combination with low-dose prednisolone (≤10mg/day) as maintenance treatment for lupus nephritis.

Eligibility criteria:
inclusion criteria: * diagnosis of lupus nephritis. * currently receiving maintenance therapy with azathioprine, mycophenolate mofetil, mycophenolate sodium, or cyclosporine for lupus nephritis for at least 3 months prior to randomization. * stable use of low dose (≤10mg/day) oral prednisolone for lupus nephritis for at least 3 months prior to randomization. exclusion criteria: * untreated, not in need of immunosuppressive treatment (in addition to corticosteroids), currently receiving induction therapy, or not responding to azathioprine, mycophenolate mofetil or mycophenolate sodium as induction or maintenance therapy for lupus nephritis. * currently receiving or anticipated to receive cyclophosphamide or iv pulse of corticosteroids. * currently receiving continuous dialysis starting more than 2 weeks before randomization, and/or with an anticipated duration of more than 8 weeks. * previous kidney transplant or planned transplant. * presence of life threatening complications such as cerebral lupus or severe infection. * presence of liver dysfunction. * presence of copd or asthma requiring oral steroids. * presence of bone marrow insufficiency or pure red cell aplasia unrelated to active systemic lupus erythematosus. * presence of persistent hematuria or pyuria for causes other than lupus nephritis.

Keywords: systemic lupus erythematosus lupus nephritis mycophenolate mofetil azathioprine maintenance therapy prednisolone serum albumin serum creatinine spot urine protein/creatinine ratio
topical as101 for treatment of faga (female androgenetic alopecia) in menopause women

Conditions: Alopecia

Summary: the primary objective of this study is to assess the safety and efficacy of topical as101 as treatment for female androgenetic alopecia (faga) in menopause women.


Eligibility criteria:
inclusion criteria: * women in menopause, over 50 years of age. * clinically diagnosed for aga, according to ludwig scale i-ii. exclusion criteria: * women treated with chronic medications. * use of minoxidil within 3 months prior to entering study. * women who have underwent hair transplantation. * use of drugs with androgenic or anti-androgenic effects. * any other type of hair loss.

Keywords: androgenetic alopecia telogen effluvium chronic telogen effluvium menopause female androgenetic alopecia (faga)
zometa and circulating vascular endothelial growth factor (vegf) in breast cancer patients with bone metastasis

Conditions: Metastatic Breast Cancer; Bone Metastases

Summary: the primary objective of this study is to evaluate the effects of zometa (zoledronic acid, 1 mg per week versus 4 mg every four weeks) on the circulating vascular endothelial growth factor (vegf) levels in breast cancer patients with bone metastases. sixty patients will be randomized into two groups.

the administration of zometa in short intervals has been implied to be more potent in maximizing its antitumor and antiangiogenesis effects, while dosing every four weeks is an appropriate strategy for the prevention and management of bone metastases. this study was designed to explore the relationship between dosing of zometa and level of circulating vegf.

Eligibility criteria:
inclusion criteria: * signed informed consent * female, 18 years or older * histologically confirmed invasive breast cancer * bone metastases * ecog performance status of 0 to 2 * life expectancy of more than 3 months * subject must have adequate organ function: * cr ≤ 3 mg/dl (265 µmol/l)， * crcl (cockcroft \& gault) ≥ 30 ml/min， * ca2+ \> 8.0 mg/dl (2.0 mmol/l) and ≤ 12 mg/dl (3.0 mmol/l) * negative serum pregnancy test for women with childbearing potential * good conditions for infusion and willing to undergo phlebotomy during the whole study * have ceased anti-tumor treatment including chemotherapy, endocrinotherapy and bio-targeted therapy for over 28 days exclusion criteria: * pregnant or lactating females * history of other malignancy. however, subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible. * concurrent disease or condition that would make the subject inappropriate for study participation, or any serious medical disorder that would interfere with the subject's safety * active or uncontrolled infection * current active dental problems including infection of the teeth or jawbone (maxilla or mandible); dental or fixture trauma; or a current or prior diagnosis of osteonecrosis of the jaw (onj); or exposed bone in the mouth; or slow healing after dental procedures * recent (within 6 weeks of randomization) or planned dental or jaw surgery (e.g. extraction, implants) * known history of uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure * concomitant with liver, brain or symptomatic lung metastases (symptoms such as hemoptysis, severe cough and shortness of breath) * accepted radiotherapy for solitary bone disease within 30 days before study * previous treatment with other bisphosphonates or radionuclides within one month before study * known hypersensitivity to bisphosphonates * history of treatment with calcitonin, gallium nitrate or mithracin within 14 days before study.

Keywords: breast cancer bone metastasis circulating vegf zoledronic acid angiogenesis
quantification of internal training load

Conditions: Hypertrophy; Resistance Training; Muscle

Summary: the aim of this study is to determine whether the distribution of internal load predicts the distribution of muscle hypertrophy among hamstring heads after a 10-week resistance exercise program. the hypothesis is that the distribution of internal muscle load among the hamstring is related to the distribution of muscle hypertrophy.

it is well accepted that muscle stress (mechanical and/or metabolic) is the major way to induce muscle hypertrophy. while this link between muscle stress and hypertrophy is pivotal is sport training, prevention and rehabilitation, it remains poorly understood. to date, the only indirect evidence of relationship of muscle stress and muscle hypertrophy is the similar patterns (from independent studies) between muscle damage and hypertrophy within quadriceps (i.e., rectus femoris (rf) \> vastus (vl) = vastus medialis vm), hamstring, and triceps surae. however, muscle damage is an indirect proof of muscle mechanical stress. with the quantification of internal muscle load, it is interesting to determine whether the muscle that receives the larger stress exhibits the larger hypertrophy.

Eligibility criteria:
inclusion criteria: * no history of lower limb injury * no chronic pathology associated with a long term care exclusion criteria: * individual enrolled in a research study

Keywords: muscle activation muscle volume muscle stress muscle mass
prostate cancer antigen 3 (pca-3) gene project

Conditions: Prostate Cancer; Benign Prostatic Hypertrophy

Summary: nowadays, prostate cancer screening is largely widespread although it is not recommended yet. this screening includes primarily digital rectal examination and psa. recently, a new specific genetic marker of prostate cancer has been discovered. it is pca-3 gene. the main objective is to evaluate prospectively this new marker in patients treated for prostatic pathology (benign or malign) in the department.

nowadays, prostate cancer screening is largely widespread although it is not recommended yet. this screening includes primarily digital rectal examination and psa. the main drawback is the poor psa specificity. prostate cancer diagnosis is only histologic diagnosis (mainly by prostate biopsies). however, prostate needle biopsies have a poor rentability and are negative in 60 to 80%. recently, a new specific genetic marker of prostate cancer has been discovered. it is pca-3 gene. this gene encodes for rnam noncoding. so, rna expression must be assayed by rt-pcr. the main objective is to evaluate prospectively this new marker in patients treated for prostatic pathology (benign or malign) in the department. pca-3 assay will be made from urine specimens collected by vesical catheterism just before surgery. moreover, the investigators will analyse expression of several prostatic markers (genes coding for androgen receptor and steroid alpha-reductase type 1 and 2). the main objective is to improve the prostate cancer diagnosis specificity. gene expression will be assayed by rt-pcr. prostatic cells in urine specimens will be confirmed by assay of psa gene expression. normalization of data will be performed using 3 housekeeping genes expression (ß-actin, k-a-1 tubulin and glyceraldehyde-3-phosphate). the originality of this clinical study compared to previous reports, consists to two elements. firstly, all patients included in our study will be operated for a prostate cancer or a bph. so, the risk to ignore a prostate cancer will be low unlike prostate biopsies made for a prostate cancer screening. secondly, pca-3 assay will be coupled with others prostatic specific markers.

Eligibility criteria:
inclusion criteria: * patients operated for a prostate cancer or a benign prostatic hypertrophy * patients not in state of emergency exclusion criteria: * patients with an urinary infection proved bacteriologically * patients with a vesical malign disease * patients in state of emergency

Keywords: prostate cancer benign prostatic hypertrophy
use of a monitor in me/cfs

Conditions: Chronic Fatigue Syndrome

Summary: the use of an activity monitor to determine increase or decrease of activity in patients suffering from chronic fatigue syndrome.

a cohort of 50 patients suffering from chronic fatigue syndrome will be given an informed release form. have a signed the informed release they will be given a fitbit activity monitor. these monitors will be evaluated on a weekly interval by computer interface. the activity will be calculated to determine the online of activity and whether there is increase or decrease in activity during the time of the study. the study is an observational rather than an interventional study. there is no invasion or intervention in the patient's normal activities

Eligibility criteria:
inclusion criteria: fukuda and canadian consensus criteria for the diagnosis of chronic fatigue syndrome exclusion criteria: acute disease and exclusion conditions in fukuda criteria

Keywords: chronic fatigue syndrome cfs myalgic encephalomyelitis m.e. activity monitor